ReviewFrontiers in cellular and infection microbiology2026
The gut microbiota-enteric nervous system axis: from bidirectional programming to precision therapeutics in digestive diseases.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bidirectional communication between the gut microbiota (GM) and the enteric nervous system (ENS) is fundamental for gastrointestinal homeostasis. This review dissects the intricate GM-ENS dialogue, emphasizing its transition from a developmental programmer in early life to a sustained regulator of neural plasticity in adulthood. We synthesize the core signaling mechanisms-microbial metabolites, neuroactive substances, and immune mediators-that orchestrate ENS activity. We further propose a multi-timescale model (rapid neuropod/bioelectric, intermediate metabolite, slow immune) with differential relevance to irritable bowel syndrome (IBS) (fast distortions) versus inflammatory bowel disease(IBD)(slow amplification). Critically, we delineate how this axis adopts distinct pathophysiological roles across major digestive disorders: acting as a "signal distorter" in IBS, an "inflammation amplifier" in IBD, and a "tumor accomplice" in colorectal cancer (CRC). By integrating these mechanistic insights with emerging therapeutic paradigms (e.g., precision biomarkers, synthetic microbial consortia, postbiotics), we position the GM-ENS axis as a central hub for understanding disease pathogenesis and a promising framework for developing next-generation precision medicine strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.